Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.

Rhew DC, Tu GS, Ofman J, Henning JM, Richards MS, Weingarten SR.

Arch Intern Med. 2001 Mar 12;161(5):722-7.

PMID:
11231705
2.
3.

Strategies for early discharge of the hospitalized patient with community-acquired pneumonia.

Siegel RE.

Clin Chest Med. 1999 Sep;20(3):599-605. Review.

PMID:
10516907
4.

Early switch to oral treatment in patients with moderate to severe community-acquired pneumonia: a meta-analysis.

Athanassa Z, Makris G, Dimopoulos G, Falagas ME.

Drugs. 2008;68(17):2469-81. doi: 10.2165/0003495-200868170-00005.

PMID:
19016574
5.

Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial.

Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, Armengou-Arxé A, Bisbe-Company V, Peñarroja-Matutano G, Bisbe-Company J, García-Bragado F.

Am J Med. 2001 Oct 1;111(5):367-74.

PMID:
11583639
6.

In-hospital observation after antibiotic switch in pneumonia: a national evaluation.

Nathan RV, Rhew DC, Murray C, Bratzler DW, Houck PM, Weingarten SR.

Am J Med. 2006 Jun;119(6):512.e1-7.

PMID:
16750965
7.

Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.

Feldman RB, Rhew DC, Wong JY, Charles RA, Goetz MB; American Thoracic Society.

Arch Intern Med. 2003 Jul 28;163(14):1718-26.

PMID:
12885688
9.

Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians.

Rifkin WD, Conner D, Silver A, Eichorn A.

Mayo Clin Proc. 2002 Oct;77(10):1053-8.

PMID:
12374249
10.

Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.

Carratalà J, Garcia-Vidal C, Ortega L, Fernández-Sabé N, Clemente M, Albero G, López M, Castellsagué X, Dorca J, Verdaguer R, Martínez-Montauti J, Manresa F, Gudiol F.

Arch Intern Med. 2012 Jun 25;172(12):922-8. doi: 10.1001/archinternmed.2012.1690.

PMID:
22732747
11.

Achieving a safe and early discharge for patients with community-acquired pneumonia.

Rhew DC, Weingarten SR.

Med Clin North Am. 2001 Nov;85(6):1427-40. Review.

PMID:
11686189
12.

Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.

Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH.

Arch Intern Med. 1999 Nov 22;159(21):2576-80.

PMID:
10573047
13.

Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.

Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, Newman D, Burke J, Mushtaq M, Huang A.

Arch Intern Med. 1999 Nov 8;159(20):2449-54.

PMID:
10665893
14.

A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.

Schein J, Janagap-Benson C, Grant R, Sikirica V, Doshi D, Olson W.

Curr Med Res Opin. 2008 Mar;24(3):895-906. doi: 10.1185/030079908X273408.

PMID:
18419876
15.

Community-acquired pneumonia: influence of management practices on length of hospital stay.

Laing R, Coles C, Chambers S, Frampton C, Jennings L, Karalus N, Mills G, Town GI.

Intern Med J. 2004 Mar;34(3):91-7.

PMID:
15030455
16.
17.
18.

Switch therapy in community-acquired pneumonia.

Ramirez JA.

Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):219-23.

PMID:
7587043
20.

Treatment and outcomes of community-acquired pneumonia at Canadian hospitals.

Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK.

CMAJ. 2000 May 16;162(10):1415-20.

Supplemental Content

Support Center